| Powder: | Yes |
|---|---|
| Customized: | Customized |
| Certification: | GMP, HSE, ISO 9001, USP, BP |
| Suitable for: | Adult |
| State: | Powder |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product Name | Velpatasvir |
| Appearance | White Powder |
| CAS No | 1377049-84-7 |
| MF | C49H54N8O8 |
Velpatasvir is innovated by Gilead to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used together with Sofosbuvir. The mechanism of action is as a Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Anion Transporting Polypeptide 2B1 Inhibitor. It blocks NS5A, a protein necessary for hepatitis C virus replication assembly.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}